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ously reported. As current catheter devices were being
developed and refined, traditional surgical approaches
were also being altered by the development of less
invasive techniques such as partial sternotomies and
much smaller skin incisions. Berger and colleagues
have evaluated a consecutive series of 102 patients who
underwent ASD closure with surgery (n = 61) or an
Amplatzer device (n = 61) during a 1-year interval
beginning May 1997. Their series begins with the first
patient to undergo device closure in their institution.
Although this evaluation was prospective, the patients
were not randomized. The patients undergoing surgery
were older and had larger defects and larger shunts. In
fact, the surgical series essentially consisted of those
patients in whom device closure was not possible. In
addition, the median age of the patients in both groups
was much older than that of the usual patient currently
undergoing ASD closure. The ASD closure rate was
98% in each group, and there were no deaths. Two
patients undergoing surgical treatment had significant
complications, and in 1 patient the Amplatzer device
embolized, requiring surgical retrieval. Length of stay
was shorter in the patients receiving the Amplatzer
device (3 days) than in those treated surgically (8 days).
On the basis of the similar outcomes, the absence of
need for blood products, and the decreased length of
stay, the authors conclude that the Amplatzer device is
preferable to surgical closure of ASDs.
Despite the fact that the series are concurrent and
from the same institution, the report is flawed by the
fact that the 2 groups are not comparable, as is pointed
out by the authors. True randomization into compara-
ble series could have been achieved by including only
those patients who were suitable for either surgical or
device closure, and the results would have been more
meaningful. Most patients undergoing surgical closure
of ASD now are discharged in 3 days or less, and it is
unfair to use decreased length of stay in this series as a
reason for the superiority of the Amplatzer device.
However, in our institution, as noted below, most
patients receiving the device are discharged in 24
hours. The authors have fairly presented one of the
major complications of device closure, that is, emboli-
zation. Although uncommon, it is potentially the cause
of a very unsatisfactory outcome (stroke or death) in a
patient with a relatively benign defect. Despite these
criticisms, the authors have indeed demonstrated the
ability to successfully close secundum ASDs in about
half of the patients with this problem.
At the Medical University of South Carolina over the
past 23 months, 60 patients (aged 2-75 years) have under-
gone successful device closure of ASDs, and 97% were
discharged in less than 24 hours (W. Radtke, personal
communication). No significant complications have
occurred. During the same interval, 16 patients were eval-
uated by echocardiography (without the need for
catheterization, as in the series reported by Berger and
associates) and were believed to be unsuitable for device
closure. Because catheter device closure is much less
invasive, this approach probably will become increasing-
ly popular with pediatric cardiologists, patients, and fam-
ilies. With further experience and device evolution, this
technique will become applicable in a larger proportion
of patients with these defects than the 50% reported here.
It is likely, however, that a significant subset will contin-
ue to have defects unsuitable for device closure; thus sur-
gical intervention will still be required in that group.
Surgical closure should continue to provide excellent
results as in the past, but less invasive techniques offer the
possibility of decreasing morbidity.
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Commentary
It has been more than 20 years since the first report
of successful transcatheter device closure of atrial sep-
tal defects (ASDs).1 In the past decade, at least 6 dif-
ferent devices have been in widespread clinical trials;
several are now approved for use in many countries.
Past reports have compared catheter closure of ASDs
with historical surgical series. Berger and associates
are to be commended, because theirs is the first study
in which an attempt has been made to compare concur-
rent results of surgical and device closure of ASDs.
Surgery and device closure were each performed on 61
patients. Complications and efficacy of the 2 proce-
dures were similar at hospital discharge except for a
higher incidence of postprocedure atrial arrhythmias in
the surgical group.
The limitations of this study highlight the difficulties
in performing such a comparison at 1 center. The sur-
gical group was composed entirely of patients who
were deemed inappropriate for the Amplatzer device,
in most cases because their ASDs were too large or had
an inadequate rim of septum to secure the device. Over
two thirds of the patients who ultimately underwent
surgical closure had previously gone to the catheteriza-
tion laboratory with the intent of device closure. Not
surprisingly, patients who underwent surgery were
older, had larger defects, and had bigger shunts than
those who underwent device closure. The differences
between the 2 treatment groups are of more than acad-
emic importance. As the authors note, they may be
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implicated as a cause for the higher incidence of atrial
flutter and fibrillation after surgery. Even accepting the
fact that there were major differences in patient popu-
lation between the arms of this study, it seems very
unlikely that surgery in a comparable group would
have been associated with significantly fewer compli-
cations than device closure.
Although the limited follow-up of most reports may
make it a bit overly enthusiastic to conclude that device
closure is now the preferred method of ASD repair, it is
reasonable and appropriate to conclude that device clo-
sure is a viable and acceptable means of closing appro-
priately selected ASDs. The fact that such a statement
can be made is a testament to the remarkable advances
made in the design and application of ASD closure
devices over the past 10 years. Improvements that cur-
rent devices incorporate include systems deliverable
through sheaths small enough for very small children,
materials increasingly resistant to fatigue, and self-cen-
tering characteristics that have reduced residual leaks
after device closure. The diversity of designs should
permit an increasing percentage of secundum defects to
be successfully closed.
We can anticipate continued refinement of ASD clo-
sure devices in the near future. Along with improve-
ments in technology, the field requires parallel
improvements in our ability to select patients appropri-
ate for device closure, minimizing the number who
undergo catheterization unnecessarily. The thoughtful
evaluation of these procedures demands carefully con-
structed prospective comparisons of catheter and surgi-
cal ASD closure. This is particularly true in light of
recent changes in the surgical approach to ASD clo-
sure. Such studies cannot be accomplished by a single
center and will be costly. Because they should not be
restricted to a single type of device, industry will not
support them. Thus such studies are likely to be con-
ducted only with governmental funding.
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